Therapeutic Strategies in Lymphoid Malignancies brings together a series of topical discussions of how the new immunotherapeutic agents can be used successfully to treat lymphoid malignancies.

Features:

• Concise and up-to-date reviews of the latest clinical developments
• An international team of contributors drawing on numerous centers of excellence
• Strategies to select appropriate therapeutic options for individual patients

Contents

• The history of immunotherapy for lymphoid malignancies
• Immunologic markers of lymphoid malignancies
• Diagnostic and prognostic markers of lymphoid malignancies; the latest genetic, cytogenic and haematologic parameters
• CD20 as a target for immunotherapy
• Rituximab and chemotherapy: improved response and survival
• Rituximab and chemotherapy in the elderly
• The role of rituximab as maintenance therapy for patients with indolent non-Hodgkin's lymphoma
• Is there a role for interferon-alpha for lymphoid malignancies
• Radioimmunotherapy safety: radiation protection, administration guidelines, isotope comparisons and quality of life issues
• Yttrium-90-ibritumomab tiuxetan radioimmunotherapy for low-grade non-Hodgkin's lymphoma
• Biodistribution of ibritumomab tiuxetan
• The role of radioimmunotherapy combined with other treatment regimens for non-Hodgkin's lymphoma
• Tositumomab: new radioimmunotherapy for the treatment of low-grade non-Hodgkin's lymphoma
• CD52 as a target for immunotherapy
• The therapeutic role of alemtuzumab in patients with CLL refractory to other treatments
• Alemtuzumab as first-line treatment for patients with B-cell lymphoproliferative disorders
• Alemtuzumab in combination with other therapies
• The role of alemtuzumab (or monoclonal antibodies) in allogeneic stem cell transplantation
• Alemtuzumab in T-cell malignancies
• Epratuzumab: A new monoclonal antibody to CD22 in development
• Patient education

Index

click here to see books • videos • cd-roms of related interest